Navigating Acute Myeloid Leukemia Treatment: Therapy-Related & De Novo AML with Dr. Naval Daver

In this episode of the Oncology Brothers podcast, we discussed two challenging cases focused on Acute Myeloid Leukemia (AML). We welcomed Dr. Naval Daver, a leading expert from MD Anderson Cancer Center, to discuss: therapy-related AML and de novo AML where induction chemotherapy is not an option. Episode Highlights: Overview of therapy-related AML and its increasing prevalence due to advancements in solid tumor treatments. In-depth discussion on the prognosis and treatment options for patients with complex cytogenetics. Comparison of induction treatments: CPX-351 vs. the traditional 7 + 3 regimen, including survival rates and side effects. Insights into the use of hypomethylating agents combined with venetoclax for older patients with AML, particularly those with NPM1 mutations. Practical considerations for administering these treatments in both inpatient and outpatient settings. Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable insights into the complexities of AML management.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/  Don't forget to subscribe for more discussions on treatment algorithms, conference highlights, and the latest FDA approvals! #AcuteMyeloidLeukemia, #TherapyRelatedAML, #DeNovoAML, #TransplantIneligible, #OncologyBrothers